Carol Sartorius
Concepts (329)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, Progesterone | 37 | 2026 | 356 | 6.450 |
Why?
| | Breast Neoplasms | 56 | 2026 | 2456 | 6.140 |
Why?
| | Progesterone | 14 | 2021 | 255 | 3.370 |
Why?
| | Keratin-5 | 9 | 2022 | 48 | 3.140 |
Why?
| | Receptors, Estrogen | 28 | 2026 | 457 | 2.960 |
Why?
| | Progestins | 13 | 2025 | 87 | 2.600 |
Why?
| | Neoplastic Stem Cells | 12 | 2020 | 412 | 2.140 |
Why?
| | Estrogens | 10 | 2026 | 380 | 1.560 |
Why?
| | Cell Line, Tumor | 29 | 2026 | 3550 | 1.470 |
Why?
| | RNA Polymerase III | 2 | 2025 | 34 | 1.420 |
Why?
| | Drug Resistance, Neoplasm | 10 | 2026 | 883 | 1.410 |
Why?
| | Estrogen Receptor alpha | 6 | 2025 | 161 | 1.280 |
Why?
| | Receptors, Androgen | 6 | 2026 | 153 | 1.060 |
Why?
| | Cancer-Associated Fibroblasts | 2 | 2024 | 23 | 0.970 |
Why?
| | Gene Expression Regulation, Neoplastic | 18 | 2026 | 1462 | 0.970 |
Why?
| | Fatty Acid Synthase, Type I | 1 | 2025 | 11 | 0.890 |
Why?
| | Estradiol | 9 | 2025 | 533 | 0.850 |
Why?
| | RNA, Transfer | 1 | 2025 | 144 | 0.850 |
Why?
| | Lipid Metabolism | 2 | 2025 | 528 | 0.820 |
Why?
| | Xenograft Model Antitumor Assays | 11 | 2026 | 930 | 0.770 |
Why?
| | Keratin-17 | 1 | 2022 | 4 | 0.750 |
Why?
| | Antineoplastic Agents, Hormonal | 11 | 2025 | 194 | 0.750 |
Why?
| | Triglycerides | 1 | 2025 | 521 | 0.750 |
Why?
| | Transcription, Genetic | 7 | 2025 | 1496 | 0.730 |
Why?
| | Cell Proliferation | 15 | 2025 | 2499 | 0.730 |
Why?
| | Repressor Proteins | 1 | 2025 | 437 | 0.720 |
Why?
| | Tamoxifen | 8 | 2025 | 217 | 0.710 |
Why?
| | Mammary Glands, Animal | 3 | 2012 | 128 | 0.650 |
Why?
| | Biomarkers, Tumor | 8 | 2022 | 1322 | 0.650 |
Why?
| | Carcinoma, Lobular | 1 | 2020 | 56 | 0.610 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2020 | 88 | 0.610 |
Why?
| | Female | 57 | 2026 | 78376 | 0.580 |
Why?
| | Mice | 35 | 2026 | 18365 | 0.550 |
Why?
| | beta Catenin | 1 | 2020 | 253 | 0.530 |
Why?
| | Retinoic Acid Receptor alpha | 1 | 2017 | 16 | 0.530 |
Why?
| | Receptors, Retinoic Acid | 1 | 2017 | 42 | 0.520 |
Why?
| | Stem Cells | 2 | 2011 | 627 | 0.490 |
Why?
| | MicroRNAs | 4 | 2015 | 701 | 0.470 |
Why?
| | Fibroblast Growth Factor 2 | 2 | 2026 | 93 | 0.470 |
Why?
| | Humans | 71 | 2026 | 144957 | 0.460 |
Why?
| | Animals | 41 | 2026 | 38109 | 0.460 |
Why?
| | Triple Negative Breast Neoplasms | 2 | 2015 | 216 | 0.460 |
Why?
| | Tumor Suppressor Proteins | 2 | 2015 | 321 | 0.450 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2015 | 49 | 0.450 |
Why?
| | Astrocytes | 2 | 2026 | 224 | 0.450 |
Why?
| | Mice, SCID | 6 | 2020 | 369 | 0.450 |
Why?
| | Paracrine Communication | 1 | 2015 | 67 | 0.450 |
Why?
| | Neoplasms, Hormone-Dependent | 2 | 2012 | 41 | 0.430 |
Why?
| | STAT5 Transcription Factor | 1 | 2014 | 52 | 0.430 |
Why?
| | Signal Transduction | 10 | 2026 | 5233 | 0.410 |
Why?
| | Cisplatin | 1 | 2015 | 334 | 0.400 |
Why?
| | Mice, Inbred NOD | 5 | 2020 | 610 | 0.400 |
Why?
| | Tumor Cells, Cultured | 10 | 2020 | 919 | 0.380 |
Why?
| | Gene Expression Profiling | 13 | 2020 | 1786 | 0.380 |
Why?
| | MCF-7 Cells | 8 | 2025 | 135 | 0.370 |
Why?
| | Tumor Microenvironment | 7 | 2021 | 735 | 0.370 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2026 | 58 | 0.370 |
Why?
| | Heterografts | 5 | 2020 | 144 | 0.370 |
Why?
| | Brain Neoplasms | 2 | 2026 | 1322 | 0.360 |
Why?
| | Ovarian Neoplasms | 2 | 2015 | 586 | 0.350 |
Why?
| | Medroxyprogesterone Acetate | 2 | 2015 | 37 | 0.350 |
Why?
| | Transcriptome | 4 | 2020 | 1046 | 0.340 |
Why?
| | Wnt Signaling Pathway | 2 | 2026 | 210 | 0.340 |
Why?
| | Mammary Glands, Human | 1 | 2011 | 67 | 0.340 |
Why?
| | Hyaluronan Receptors | 6 | 2014 | 102 | 0.320 |
Why?
| | Carcinogenesis | 2 | 2020 | 229 | 0.270 |
Why?
| | Estrogen Replacement Therapy | 1 | 2008 | 144 | 0.260 |
Why?
| | Chromatin | 2 | 2025 | 561 | 0.250 |
Why?
| | Antineoplastic Agents | 2 | 2015 | 2197 | 0.250 |
Why?
| | Androgens | 2 | 2021 | 186 | 0.250 |
Why?
| | Promoter Regions, Genetic | 6 | 2025 | 1258 | 0.240 |
Why?
| | Neural Cell Adhesion Molecules | 1 | 2026 | 38 | 0.240 |
Why?
| | Mice, Nude | 6 | 2015 | 688 | 0.240 |
Why?
| | Transcription Factor TFIIIB | 1 | 2025 | 5 | 0.240 |
Why?
| | TATA-Binding Protein Associated Factors | 1 | 2025 | 22 | 0.230 |
Why?
| | Transplantation, Heterologous | 6 | 2016 | 194 | 0.230 |
Why?
| | Lymphatic Metastasis | 5 | 2017 | 334 | 0.230 |
Why?
| | Apoptosis | 6 | 2017 | 2430 | 0.220 |
Why?
| | Antigens, CD | 2 | 2020 | 555 | 0.220 |
Why?
| | Models, Theoretical | 1 | 2008 | 582 | 0.220 |
Why?
| | DNA-Binding Proteins | 3 | 2015 | 1500 | 0.210 |
Why?
| | Disease Progression | 6 | 2026 | 2852 | 0.210 |
Why?
| | Myosin Heavy Chains | 3 | 2001 | 185 | 0.210 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2016 | 339 | 0.200 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2022 | 1141 | 0.200 |
Why?
| | Down-Regulation | 3 | 2015 | 627 | 0.200 |
Why?
| | Pharmacology, Clinical | 1 | 2023 | 9 | 0.200 |
Why?
| | Cyclic AMP | 3 | 1995 | 209 | 0.200 |
Why?
| | Mammary Neoplasms, Experimental | 2 | 2020 | 70 | 0.190 |
Why?
| | Neoplasm Transplantation | 3 | 2016 | 252 | 0.190 |
Why?
| | Mammary Neoplasms, Animal | 1 | 2022 | 34 | 0.190 |
Why?
| | Nuclear Proteins | 2 | 2015 | 749 | 0.190 |
Why?
| | Cell Communication | 1 | 2024 | 324 | 0.180 |
Why?
| | Homeodomain Proteins | 3 | 2018 | 524 | 0.180 |
Why?
| | Vimentin | 1 | 2022 | 54 | 0.180 |
Why?
| | Gene Knockout Techniques | 2 | 2020 | 116 | 0.180 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2022 | 33 | 0.180 |
Why?
| | Cell Division | 1 | 2003 | 766 | 0.170 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2015 | 531 | 0.170 |
Why?
| | Insulin Receptor Substrate Proteins | 1 | 2020 | 55 | 0.160 |
Why?
| | Transcription Factors | 5 | 2023 | 1742 | 0.160 |
Why?
| | Leukocytes, Mononuclear | 2 | 2020 | 573 | 0.160 |
Why?
| | Thyroid Hormones | 1 | 2020 | 67 | 0.160 |
Why?
| | Antigens, Nuclear | 1 | 2000 | 16 | 0.160 |
Why?
| | Doxorubicin | 1 | 2022 | 397 | 0.160 |
Why?
| | Adherens Junctions | 1 | 2020 | 24 | 0.160 |
Why?
| | Neoplasm Metastasis | 2 | 2020 | 695 | 0.150 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2020 | 82 | 0.150 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2000 | 86 | 0.150 |
Why?
| | Immunoprecipitation | 1 | 2020 | 151 | 0.150 |
Why?
| | Hormone Replacement Therapy | 1 | 2020 | 106 | 0.150 |
Why?
| | Protein Isoforms | 3 | 2019 | 402 | 0.150 |
Why?
| | Saccharomyces cerevisiae Proteins | 2 | 2001 | 419 | 0.150 |
Why?
| | Neoplasm Invasiveness | 3 | 2020 | 509 | 0.150 |
Why?
| | Binding Sites | 7 | 2025 | 1331 | 0.150 |
Why?
| | Protein Interaction Mapping | 1 | 2020 | 105 | 0.150 |
Why?
| | Up-Regulation | 2 | 2020 | 852 | 0.150 |
Why?
| | Cluster Analysis | 4 | 2019 | 521 | 0.150 |
Why?
| | Forkhead Box Protein O1 | 1 | 2019 | 36 | 0.150 |
Why?
| | Disease Susceptibility | 1 | 2021 | 348 | 0.140 |
Why?
| | Tretinoin | 2 | 2017 | 124 | 0.140 |
Why?
| | DNA Helicases | 1 | 2000 | 143 | 0.140 |
Why?
| | Mass Spectrometry | 2 | 2020 | 750 | 0.140 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2020 | 220 | 0.140 |
Why?
| | Cadherins | 1 | 2020 | 201 | 0.140 |
Why?
| | Risk | 1 | 2021 | 911 | 0.140 |
Why?
| | Models, Biological | 3 | 2019 | 1822 | 0.130 |
Why?
| | Cell Culture Techniques | 1 | 2020 | 375 | 0.130 |
Why?
| | 8-Bromo Cyclic Adenosine Monophosphate | 2 | 1994 | 20 | 0.130 |
Why?
| | Cell Movement | 2 | 2026 | 965 | 0.130 |
Why?
| | Models, Neurological | 1 | 2019 | 254 | 0.120 |
Why?
| | Bayes Theorem | 1 | 2019 | 433 | 0.120 |
Why?
| | Glucose Transporter Type 1 | 1 | 2016 | 48 | 0.120 |
Why?
| | Lipids | 1 | 2021 | 710 | 0.120 |
Why?
| | Software | 2 | 2019 | 692 | 0.120 |
Why?
| | Phenylthiohydantoin | 1 | 2016 | 44 | 0.120 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 442 | 0.120 |
Why?
| | ErbB Receptors | 2 | 2020 | 629 | 0.120 |
Why?
| | Cell Membrane | 1 | 2020 | 706 | 0.120 |
Why?
| | Tissue Array Analysis | 1 | 2015 | 50 | 0.120 |
Why?
| | Single-Cell Analysis | 1 | 2019 | 359 | 0.110 |
Why?
| | CD146 Antigen | 3 | 2021 | 40 | 0.110 |
Why?
| | Ribosomal Proteins | 1 | 2015 | 91 | 0.110 |
Why?
| | Disease Models, Animal | 4 | 2016 | 4569 | 0.110 |
Why?
| | Transcriptional Activation | 3 | 2006 | 383 | 0.110 |
Why?
| | Gene Knockdown Techniques | 1 | 2015 | 336 | 0.110 |
Why?
| | Molecular Sequence Data | 7 | 2012 | 2931 | 0.110 |
Why?
| | Mutation | 4 | 2022 | 4099 | 0.110 |
Why?
| | Azepines | 1 | 2015 | 107 | 0.110 |
Why?
| | Phenotype | 4 | 2011 | 3164 | 0.100 |
Why?
| | Glycoproteins | 1 | 2015 | 355 | 0.100 |
Why?
| | Brain | 1 | 2026 | 2941 | 0.100 |
Why?
| | Neoadjuvant Therapy | 2 | 2021 | 463 | 0.100 |
Why?
| | Immunohistochemistry | 2 | 2015 | 1718 | 0.100 |
Why?
| | Peptide Fragments | 3 | 2003 | 699 | 0.100 |
Why?
| | Endometrial Neoplasms | 1 | 2015 | 208 | 0.100 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2012 | 758 | 0.100 |
Why?
| | Ligands | 3 | 2023 | 674 | 0.100 |
Why?
| | CD24 Antigen | 1 | 2012 | 18 | 0.090 |
Why?
| | RNA, Messenger | 2 | 2019 | 2832 | 0.090 |
Why?
| | Muscle, Skeletal | 3 | 2001 | 1796 | 0.090 |
Why?
| | Breast Neoplasms, Male | 1 | 2012 | 29 | 0.090 |
Why?
| | Mifepristone | 3 | 2020 | 64 | 0.090 |
Why?
| | Retinoids | 1 | 2012 | 33 | 0.090 |
Why?
| | Cell Survival | 1 | 2015 | 1098 | 0.090 |
Why?
| | Liver Neoplasms | 1 | 2019 | 783 | 0.090 |
Why?
| | Gene Regulatory Networks | 2 | 2012 | 320 | 0.090 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2012 | 78 | 0.090 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 173 | 0.090 |
Why?
| | Cell Differentiation | 2 | 2012 | 2050 | 0.090 |
Why?
| | Small Molecule Libraries | 1 | 2012 | 111 | 0.080 |
Why?
| | Drug Discovery | 1 | 2012 | 155 | 0.080 |
Why?
| | Cell Nucleus | 3 | 2026 | 619 | 0.080 |
Why?
| | Pyrimidines | 1 | 2015 | 533 | 0.080 |
Why?
| | Tumor Burden | 1 | 2012 | 322 | 0.080 |
Why?
| | Receptors, Notch | 1 | 2011 | 92 | 0.080 |
Why?
| | HeLa Cells | 4 | 2006 | 650 | 0.080 |
Why?
| | Cell Size | 1 | 2010 | 92 | 0.080 |
Why?
| | HEK293 Cells | 1 | 2012 | 744 | 0.080 |
Why?
| | Peptides | 1 | 2015 | 998 | 0.080 |
Why?
| | Ovariectomy | 1 | 2010 | 162 | 0.080 |
Why?
| | Peritoneal Neoplasms | 1 | 2010 | 103 | 0.080 |
Why?
| | Transforming Growth Factor beta | 1 | 2012 | 479 | 0.080 |
Why?
| | Cell Growth Processes | 2 | 2006 | 50 | 0.070 |
Why?
| | Embryonal Carcinoma Stem Cells | 1 | 2008 | 2 | 0.070 |
Why?
| | Flow Cytometry | 1 | 2012 | 1173 | 0.070 |
Why?
| | Adenocarcinoma | 1 | 2015 | 931 | 0.070 |
Why?
| | Muscle Fibers, Skeletal | 2 | 2001 | 214 | 0.070 |
Why?
| | Neoplasms, Experimental | 1 | 2008 | 173 | 0.060 |
Why?
| | Phosphorylation | 3 | 2008 | 1733 | 0.060 |
Why?
| | Kaplan-Meier Estimate | 2 | 2020 | 966 | 0.060 |
Why?
| | Histone Acetyltransferases | 1 | 2006 | 62 | 0.060 |
Why?
| | Lung Neoplasms | 1 | 2019 | 2642 | 0.060 |
Why?
| | Amino Acid Sequence | 3 | 2012 | 2157 | 0.060 |
Why?
| | Keratins | 1 | 2005 | 172 | 0.060 |
Why?
| | STAT1 Transcription Factor | 1 | 2025 | 68 | 0.050 |
Why?
| | Obesity | 1 | 2018 | 3082 | 0.050 |
Why?
| | Chloramphenicol O-Acetyltransferase | 2 | 1994 | 37 | 0.050 |
Why?
| | Organ Specificity | 2 | 2010 | 313 | 0.050 |
Why?
| | Gonanes | 2 | 1994 | 28 | 0.050 |
Why?
| | Lymph Nodes | 1 | 2006 | 502 | 0.050 |
Why?
| | Mice, Transgenic | 2 | 2020 | 2185 | 0.050 |
Why?
| | Base Sequence | 3 | 2001 | 2191 | 0.050 |
Why?
| | Genes, Reporter | 2 | 2012 | 276 | 0.050 |
Why?
| | Hepatocyte Nuclear Factor 3-alpha | 1 | 2022 | 9 | 0.050 |
Why?
| | Gene Expression Regulation | 2 | 2022 | 2609 | 0.050 |
Why?
| | Neoplasm Proteins | 1 | 2005 | 444 | 0.050 |
Why?
| | Mice, Knockout | 2 | 2020 | 3125 | 0.050 |
Why?
| | Protein Binding | 2 | 2025 | 2276 | 0.050 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2023 | 210 | 0.040 |
Why?
| | Aromatase Inhibitors | 1 | 2021 | 75 | 0.040 |
Why?
| | Nuclear Receptor Coactivator 3 | 1 | 2021 | 5 | 0.040 |
Why?
| | Cell Adhesion Molecules | 1 | 2021 | 178 | 0.040 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2021 | 53 | 0.040 |
Why?
| | Cyclin-Dependent Kinase 6 | 1 | 2021 | 49 | 0.040 |
Why?
| | Nucleosomes | 1 | 2022 | 165 | 0.040 |
Why?
| | Ku Autoantigen | 1 | 2000 | 12 | 0.040 |
Why?
| | DNA-Activated Protein Kinase | 1 | 2000 | 15 | 0.040 |
Why?
| | Neoplasms | 1 | 2015 | 2884 | 0.040 |
Why?
| | Glutathione Transferase | 1 | 2000 | 100 | 0.040 |
Why?
| | Antigens, Neoplasm | 1 | 2021 | 272 | 0.040 |
Why?
| | Methionine | 1 | 2000 | 162 | 0.040 |
Why?
| | Carrier Proteins | 1 | 2023 | 737 | 0.040 |
Why?
| | Cell Death | 1 | 2020 | 383 | 0.040 |
Why?
| | Disease-Free Survival | 1 | 2020 | 769 | 0.040 |
Why?
| | Gene Library | 1 | 2019 | 126 | 0.040 |
Why?
| | Datasets as Topic | 1 | 2019 | 122 | 0.040 |
Why?
| | DNA, Complementary | 1 | 2019 | 277 | 0.040 |
Why?
| | Loss of Function Mutation | 1 | 2018 | 46 | 0.030 |
Why?
| | B7-H1 Antigen | 1 | 2020 | 241 | 0.030 |
Why?
| | Immunologic Memory | 1 | 2020 | 366 | 0.030 |
Why?
| | Breast | 1 | 2019 | 159 | 0.030 |
Why?
| | Diaphragm | 1 | 1998 | 49 | 0.030 |
Why?
| | Uncertainty | 1 | 2019 | 145 | 0.030 |
Why?
| | Prognosis | 2 | 2020 | 4293 | 0.030 |
Why?
| | Sequence Homology, Amino Acid | 2 | 2012 | 396 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2020 | 1253 | 0.030 |
Why?
| | Myosins | 1 | 1998 | 136 | 0.030 |
Why?
| | Mutagenesis, Site-Directed | 2 | 2001 | 381 | 0.030 |
Why?
| | Protein Structure, Tertiary | 2 | 2012 | 862 | 0.030 |
Why?
| | Heterozygote | 1 | 1998 | 315 | 0.030 |
Why?
| | Recombinant Fusion Proteins | 1 | 2000 | 675 | 0.030 |
Why?
| | Dendritic Cells | 1 | 2020 | 499 | 0.030 |
Why?
| | Autoantigens | 1 | 2000 | 429 | 0.030 |
Why?
| | Protein Biosynthesis | 1 | 2000 | 458 | 0.030 |
Why?
| | Neurons | 1 | 2026 | 1642 | 0.030 |
Why?
| | Adult | 2 | 2017 | 40506 | 0.030 |
Why?
| | Adaptation, Physiological | 1 | 2001 | 570 | 0.030 |
Why?
| | Transfection | 2 | 2003 | 940 | 0.030 |
Why?
| | Cyclohexanes | 1 | 2016 | 23 | 0.030 |
Why?
| | Luminescent Measurements | 1 | 2016 | 76 | 0.030 |
Why?
| | Transduction, Genetic | 1 | 2016 | 133 | 0.030 |
Why?
| | Anilides | 1 | 2016 | 84 | 0.030 |
Why?
| | AC133 Antigen | 1 | 2015 | 20 | 0.030 |
Why?
| | Neuronal Plasticity | 1 | 2019 | 309 | 0.030 |
Why?
| | Recombinant Proteins | 2 | 2003 | 1371 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2015 | 66 | 0.030 |
Why?
| | Benzamides | 1 | 2016 | 224 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2019 | 550 | 0.030 |
Why?
| | Tumor Protein p73 | 1 | 2015 | 18 | 0.030 |
Why?
| | Nitriles | 1 | 2016 | 205 | 0.030 |
Why?
| | Cell Count | 1 | 2015 | 321 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 1998 | 1054 | 0.030 |
Why?
| | Hormone Antagonists | 1 | 1995 | 34 | 0.030 |
Why?
| | Aurora Kinase A | 1 | 2015 | 62 | 0.030 |
Why?
| | TATA Box | 1 | 1994 | 22 | 0.030 |
Why?
| | Mammary Tumor Virus, Mouse | 1 | 1994 | 45 | 0.030 |
Why?
| | Weight Gain | 1 | 2018 | 559 | 0.030 |
Why?
| | Fibroblasts | 1 | 2020 | 1034 | 0.030 |
Why?
| | Computational Biology | 1 | 2019 | 681 | 0.030 |
Why?
| | Adipose Tissue | 1 | 2018 | 653 | 0.030 |
Why?
| | Drug Synergism | 1 | 1994 | 357 | 0.030 |
Why?
| | Amino Acid Motifs | 2 | 2006 | 224 | 0.020 |
Why?
| | Promegestone | 1 | 1993 | 33 | 0.020 |
Why?
| | beta-Galactosidase | 1 | 1993 | 77 | 0.020 |
Why?
| | Raccoon Dogs | 1 | 2012 | 1 | 0.020 |
Why?
| | Foxes | 1 | 2012 | 3 | 0.020 |
Why?
| | Wolves | 1 | 2012 | 5 | 0.020 |
Why?
| | Oligodeoxyribonucleotides | 1 | 1993 | 141 | 0.020 |
Why?
| | Cell Line | 2 | 2001 | 2882 | 0.020 |
Why?
| | Acitretin | 1 | 2012 | 3 | 0.020 |
Why?
| | Miconazole | 1 | 2012 | 5 | 0.020 |
Why?
| | DNA | 2 | 2001 | 1464 | 0.020 |
Why?
| | Isotretinoin | 1 | 2012 | 26 | 0.020 |
Why?
| | CHO Cells | 1 | 2012 | 171 | 0.020 |
Why?
| | Cricetinae | 1 | 2012 | 304 | 0.020 |
Why?
| | Phosphates | 1 | 1993 | 180 | 0.020 |
Why?
| | Luciferases | 1 | 2012 | 152 | 0.020 |
Why?
| | 3' Untranslated Regions | 1 | 2012 | 152 | 0.020 |
Why?
| | Claudins | 1 | 2011 | 23 | 0.020 |
Why?
| | Glucose | 1 | 2016 | 1049 | 0.020 |
Why?
| | Species Specificity | 1 | 2012 | 574 | 0.020 |
Why?
| | Dogs | 1 | 2012 | 438 | 0.020 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2011 | 77 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2012 | 405 | 0.020 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2010 | 36 | 0.020 |
Why?
| | Diet | 1 | 2018 | 1275 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2010 | 200 | 0.020 |
Why?
| | Liver | 1 | 2019 | 1888 | 0.020 |
Why?
| | Male | 3 | 2016 | 72406 | 0.020 |
Why?
| | Cohort Studies | 1 | 2020 | 5965 | 0.020 |
Why?
| | Protein Processing, Post-Translational | 1 | 2012 | 477 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2015 | 970 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 983 | 0.020 |
Why?
| | Progesterone Congeners | 1 | 2008 | 14 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 1187 | 0.020 |
Why?
| | Microdissection | 1 | 2007 | 15 | 0.020 |
Why?
| | Lasers | 1 | 2007 | 132 | 0.020 |
Why?
| | Nuclear Receptor Coactivator 1 | 1 | 2006 | 10 | 0.020 |
Why?
| | Mutant Proteins | 1 | 2006 | 106 | 0.010 |
Why?
| | Protein Kinases | 1 | 2008 | 315 | 0.010 |
Why?
| | Lung | 1 | 2019 | 4109 | 0.010 |
Why?
| | Protein Structure, Secondary | 1 | 2006 | 369 | 0.010 |
Why?
| | COS Cells | 1 | 2003 | 181 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2005 | 1311 | 0.010 |
Why?
| | Sequence Alignment | 1 | 2003 | 368 | 0.010 |
Why?
| | Mutagenesis | 1 | 2003 | 192 | 0.010 |
Why?
| | Uterus | 1 | 2003 | 226 | 0.010 |
Why?
| | Sequence Deletion | 1 | 2001 | 193 | 0.010 |
Why?
| | Hypertrophy | 1 | 2001 | 127 | 0.010 |
Why?
| | Enhancer Elements, Genetic | 1 | 2001 | 192 | 0.010 |
Why?
| | Organ Size | 1 | 2001 | 463 | 0.010 |
Why?
| | Reference Values | 1 | 2001 | 798 | 0.010 |
Why?
| | Body Weight | 1 | 2001 | 978 | 0.010 |
Why?
| | Motor Activity | 1 | 2001 | 722 | 0.010 |
Why?
| | Aged | 1 | 2015 | 25947 | 0.010 |
Why?
| | Feeding Behavior | 1 | 2001 | 685 | 0.010 |
Why?
| | Membrane Proteins | 1 | 2001 | 1167 | 0.010 |
Why?
| | Middle Aged | 1 | 2015 | 35928 | 0.010 |
Why?
|
|
Sartorius's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|